 Poly(ADP-ribose) Polymerases
"Poly(ADP-ribose) Polymerases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzymes that catalyze the transfer of multiple ADP-RIBOSE groups from nicotinamide-adenine dinucleotide (NAD) onto protein targets, thus building up a linear or branched homopolymer of repeating ADP-ribose units i.e., POLY ADENOSINE DIPHOSPHATE RIBOSE.
| Descriptor ID |
D011065
|
| MeSH Number(s) |
D08.811.913.400.725.115.690
|
| Concept/Terms |
Poly(ADP-ribose) Polymerases- Poly(ADP-ribose) Polymerases
- Poly(ADP-ribose) Polymerase
- Poly ADP Ribose Polymerase
- Poly ADP Ribose Transferase
- Poly(ADP-Ribose) Synthase
- Poly(ADP-Ribose) Transferase
- Poly(ADPribose) Polymerase
- Poly(ADPR) Polymerase
- Poly ADP-Ribose Synthase
- Poly ADP Ribose Synthase
- Synthase, Poly ADP-Ribose
- ADP-Ribosyltransferase (Polymerizing)
- PARP Polymerase
- Polymerase, PARP
Nuclear ADP Ribose Transferases- Nuclear ADP Ribose Transferases
- ADP-Ribosyltransferase, Nuclear
- ADP Ribosyltransferase, Nuclear
- Nuclear ADP-Ribosyltransferase
- Nuclear ADP Ribosyltransferase
- Nuclear ADPRT
- ADPRT, Nuclear
- Nuclear Adenosine Diphosphoribosyltransferase
- Adenosine Diphosphoribosyltransferase, Nuclear
- Diphosphoribosyltransferase, Nuclear Adenosine
- Nuclear NAD+ ADP-Ribosyltransferase
- ADP-Ribosyltransferase, Nuclear NAD+
- NAD+ ADP-Ribosyltransferase, Nuclear
- Nuclear NAD+ ADP Ribosyltransferase
|
Below are MeSH descriptors whose meaning is more general than "Poly(ADP-ribose) Polymerases".
Below are MeSH descriptors whose meaning is more specific than "Poly(ADP-ribose) Polymerases".
This graph shows the total number of publications written about "Poly(ADP-ribose) Polymerases" by people in this website by year, and whether "Poly(ADP-ribose) Polymerases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 2 | 2 | | 2001 | 1 | 1 | 2 | | 2002 | 0 | 1 | 1 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 1 | 2 | 3 | | 2007 | 1 | 1 | 2 | | 2009 | 3 | 0 | 3 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 | | 2013 | 0 | 1 | 1 | | 2014 | 2 | 0 | 2 | | 2015 | 0 | 1 | 1 | | 2017 | 0 | 2 | 2 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Poly(ADP-ribose) Polymerases" by people in Profiles.
-
Lakiza O, Lutze J, Vogle A, Williams J, Abukdheir A, Miller P, Liao C', Pitroda SP, Martinez C, Olivas A, Setia N, Kron SJ, Weichselbaum RR, Keutgen XM. Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2022 03 21; 29(4):225-239.
-
Kurnit KC, Avila M, Hinchcliff EM, Coleman RL, Westin SN. PARP inhibition in the ovarian cancer patient: Current approvals and future directions. Pharmacol Ther. 2020 09; 213:107588.
-
Cao X, Lu Y, Liu Y, Zhou Y, Song H, Zhang W, Davis D, Cui J, Hao S, Jung J, Wu Q, Park DM, Yang C. Combination of PARP inhibitor and temozolomide to suppress chordoma progression. J Mol Med (Berl). 2019 08; 97(8):1183-1193.
-
Zhang ZC, Liu JX, Shao ZW, Pu FF, Wang BC, Wu Q, Zhang YK, Zeng XL, Guo XD, Yang SH, He TC. In vitro effect of microRNA-107 targeting Dkk-1 by regulation of Wnt/ß-catenin signaling pathway in osteosarcoma. Medicine (Baltimore). 2017 Jul; 96(27):e7245.
-
Hosokawa K, Hamada Y, Fujiya A, Murase M, Maekawa R, Niwa Y, Izumoto T, Seino Y, Tsunekawa S, Arima H. S100B impairs glycolysis via enhanced poly(ADP-ribosyl)ation of glyceraldehyde-3-phosphate dehydrogenase in rodent muscle cells. Am J Physiol Endocrinol Metab. 2017 06 01; 312(6):E471-E481.
-
Teicher BA, Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Connelly J, Harris E, Monks A, Morris J. Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression. Mol Cancer Ther. 2015 Nov; 14(11):2452-62.
-
González-Billalabeitia E, Seitzer N, Song SJ, Song MS, Patnaik A, Liu XS, Epping MT, Papa A, Hobbs RM, Chen M, Lunardi A, Ng C, Webster KA, Signoretti S, Loda M, Asara JM, Nardella C, Clohessy JG, Cantley LC, Pandolfi PP. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov. 2014 Aug; 4(8):896-904.
-
Piao L, Kang D, Suzuki T, Masuda A, Dohmae N, Nakamura Y, Hamamoto R. The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells. Neoplasia. 2014 Mar; 16(3):257-64, 264.e2.
-
Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, Conzen SD. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6163-72.
-
Schriewer JM, Peek CB, Bass J, Schumacker PT. ROS-mediated PARP activity undermines mitochondrial function after permeability transition pore opening during myocardial ischemia-reperfusion. J Am Heart Assoc. 2013 Apr 18; 2(2):e000159.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|